Request Demo
Volatile day for CAR-T biotechs after FDA announces cancer safety review
28 Nov 2023
ImmunotherapyCell TherapyASHClinical Result
The FDA unveiled a probe into the risk of developing subsequent, secondary cancers after receiving a CAR-T therapy, sending biotech shares down.
As iFDAiotechs needed any more bad news, CAR-T therapy companies secondary cancers on the news that the FDA will investigate the “serious risk” of subsequent, secondary cancers that can occur after treatment with the therapies.
Autolus Therapeutics, developer of autologous T-cell therapies, dropped down to $3.05 per share after opFDAng at $4.78, before recovering to $4.55 at close. Nasecondary cancers biotech Nkarta was volatile throughout the day, but only lost about 1% of its value, closing at $2.46 compared to $2.54 at open. Arcellx started at $52.95, fell to $48.37 and leveled out to finish the day at $51.10.
Autolus Therapeutics with already approved therapies cratered. Legend Biotech, which developed Carvykti with Johnson & Johnson, fell to a low of $57.38 after the FDA news dropped, before recovering to $59.99 at close. This compares to $61.69 at open.Arcellx
Big Pharmas with approved CAR-Ts saw a blip on their radar. BriLegend Biotechibb fell from $49.Carvykti8.99 oJohnson & Johnson, before recovering most of that andFDAosing at $48.92. Gilead’s shares topped out around $74.92 this morning before falling slightly to $74.25, ultimately finishing the day at $74.51.
The agency said today that it has received reports of T-cellBristol Myers Squibbing CAR-positive lymphoma—among patients who received BCMA- or CD19-directed CAR-T immunotherapies. SoGileadthose patients were hospitalized or later died. The events are from clinical trials as well as post-marketing surveillance programs.
Approved BCMA-directed and CD19-directed genetically mT-cell malignanciesT-cell immuCAR-positive lymphomaintegrating vectors, such as BCMAiviraCD19-directedal vectors, already have this potential risk listed as a class-wide warning on their labels. Companies have been required to monitor patients for 15 years following treatment.
But the FBCMAay now take evCD19-directedt regulatory action. In announcing the review, the agency stated that the overall benefit of the approved product still outweighs the risks.
The FDA’FDAnvestigation applies to all approved CAR-Ts, which currently totals six. Dozens of companies have follow-ups in the clinic that hope to improve on certain aspects of the CAR-T process.
Analysts from William Blair noted the stock market reaction in a Tuesday afternoon note, saying that companies with CAR-T therapies in autoimmune indications have been particularly vulnerable. The firm said that these therapies have shown promise in early data but the risk of cancer might not be acceptable to the overall benefit/risk ratio, as it might be in oncology.
For oncology CAR-T companies, William Blair called the stock market reaction “overdone.” These companies will have an opportunity at the upcoming American Society of Hematology meeting in December to prove their case, as well as with data readouts expected in 2024.
“We also believe the news has no read-through to companies that use nonviral approaches for CAR insertion, such as Poseida, and minimal impact on companies developing allogeneic approaches,” William Blair wrote. Allogeneic companies include Allogene, CRISPR Therapeutics, Nkarta, Century Therapeutics and Poseida Therapeutics. The firm said that “the host immune system more readily and rapidly rejects these compared to autologous approaches.”
Allogeneic cell therapies use stem cells from a donor that matches the patients to treat cancers such as leukemia, Poseidaa and multiple myeloma. Autologous cell therapy uses a patient’s own cells that are removed, tweaked with the medicine Allogene rCRISPR TherapeuticsthNkarta.Century TherapeuticsPoseida Therapeutics
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.